Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2011

View Archived Issues

Tamsulosin OCAS plus solifenacin in BPH-associated LUTS: SATURN results disclosed at EAU meeting

Marine product NPM-01 has neuroprotective activity

Chloroquine inhibits pancreatic tumor growth by suppressing autophagy

Researchers at the MCG Research Institute present novel modulators of F1F0 ATP synthase

Nektar begins phase I trial of NKTR-181 for the treatment of pain

European Commission approves Jevtana for second-line treatment of prostate cancer

FDA approves IND for StarGen, a novel ocular product for Stargardt's disease

Galanin GAL1 receptor agonists developed by High Point Pharmaceuticals for pain

Gilenya gains approval in Europe for multiple sclerosis

Janssen discloses novel inhibitors of fatty-acid amide hydrolase

Merck & Co. patents new mGlu2 receptor agonists for schizophrenia

Merck & Co. prepares new series of PDE10A inhibitors

S*BIO's SB-939 to enter advanced lung cancer trials in Singapore

Mucosis begins phase I study of FluGEM vaccine

Hunter Immunology begins phase IIb study of HI-164OV oral vaccine in COPD

CHMP recommends approval of Eliquis for prevention of venous thromboembolic events

EMA committee recommends new pediatric indication for Pfizer's Revatio

Curemark achieves enrollment target for phase III trials of autism therapy CM-AT

CHMP adopts positive opinion on ViroPharma's Cinryze

Photocure's Cevira PDT to be assessed in phase II trial

NanoViricides reports survival data from latest animal study of FluCide drug candidates

FDA clears Insmed's IND for phase III Arikace trial in mycobacterial lung infections

Medicago begins U.S. phase I trial of H1N1 influenza vaccine candidate

PAI-039 improves symptoms of inflammation in experimental model of chronic asthma

Calcitriol activity may prevent steroid-resistant asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...